Related Experiment Video

Updated: Jun 25, 2026

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
09:06

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner1, Philipp B Staber, Peter Neumeister

  • 1Division of Hematology, Department of Internal Medicine, Medical University of Graz, Austria.

Therapeutics and Clinical Risk Management
|February 12, 2009
PubMed

Insights

Posaconazole is a novel triazole antifungal effective against a broad spectrum of fungi, including difficult-to-treat infections. It offers a crucial treatment option for immunocompromised patients facing invasive fungal infections and resistance.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising incidence of invasive fungal infections (IFIs) in immunocompromised hosts.
  • Increasing prevalence of antifungal resistance necessitates novel therapeutic agents.
  • Triazole antifungals, like posaconazole, show promise against broad-spectrum fungi.

Purpose of the Study:

  • To review preclinical and clinical data of posaconazole.
  • To focus on posaconazole's role in treating refractory invasive fungal infections.
  • To highlight posaconazole's unique activity against zygomycetes.

Main Methods:

  • Review of preclinical studies evaluating posaconazole's in vitro and in vivo efficacy.
  • Analysis of clinical trial data assessing posaconazole's safety and effectiveness.
  • Examination of posaconazole's pharmacokinetic and pharmacodynamic properties.

Main Results:

  • Posaconazole demonstrates broad-spectrum in vitro activity against Aspergillus, Candida, zygomycetes, and Fusarium species.
  • Clinical approvals include prophylaxis for stem cell transplant recipients and neutropenic patients, and treatment for oropharyngeal candidiasis.
  • Posaconazole is effective as salvage therapy for invasive aspergillosis, fusariosis, and other mycoses.

Conclusions:

  • Posaconazole is a valuable therapeutic option for IFIs, particularly in immunocompromised populations.
  • Its activity against zygomycetes and refractory infections makes it a significant advancement in antifungal therapy.
  • Posaconazole represents a key treatment for challenging and resistant invasive fungal infections.
Keywords:
posaconazolerefractory invasive fungal infectionssalvage therapy

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).